



**GLOBAL STRATEGY FOR THE
DIAGNOSIS AND MANAGEMENT OF ASTHMA
IN CHILDREN 5 YEARS AND YOUNGER**

Available at www.ginasthma.org

COPYRIGHTED MATERIAL -DO NOT ALTER OR REPRODUCE!

Disclaimer: Although the recommendations of this document are based on the best published evidence, it is the responsibility of practicing physicians to consider the cost, benefits and risks of all treatments prescribed in young children, with due reference to recommendations and licensed formulations, dosing, and indications for use in their country.

Global Strategy for Asthma Management and Prevention in Children 5 Years and Younger

Executive Committee (2008)

Eric D. Bateman, MD, *Chair*
Cape Town, South Africa

Louis-Philippe Boulet, MD
Sainte-Foy, Quebec, Canada

Alvaro Cruz, MD
Salvador, Brazil

Mark FitzGerald, MD
Vancouver, BC, Canada

Tari Haahtela, MD
Helsinki, Finland

Mark Levy, MD
London, England, UK

Paul O'Byrne, MD
Ontario, Canada

Ken Ohta, MD
Tokyo, Japan

Pierluigi Paggiaro, MD
Pisa, Italy

*Soren Erik Pedersen, MD
Kolding, Denmark

*Manuel Soto-Quiroz, MD
San José, Costa Rica

Wan-Cheng Tan, MD
Vancouver, BC, Canada

*Gary W. Wong, MD
Hong Kong ROC

GINA Science Committee

Mark FitzGerald, MD, *Chair*
Vancouver, BC, Canada

Peter J. Barnes, MD
London, England, UK

Neil Barnes, MD
London, England, UK

Eric D. Bateman, MD
Cape Town, South Africa

*Allan Becker, MD
Winnipeg, Manitoba, Canada

Jeffrey M. Drazen, MD
Boston, MA, USA

*Robert F. Lemanske, Jr, MD
Madison, WI, USA

Paul O'Byrne, MD
Hamilton, Ontario, Canada

Ken Ohta, MD, PhD
Tokyo, Japan

Soren Erik Pedersen, MD
Kolding, Denmark

Emilio Pizzichini, MD
Florianópolis, Brazil

Helen K. Reddel, MD
NSW, Australia

Sean D. Sullivan, PhD
Seattle, WA, USA

Sally E. Wenzel, M.D.
Pittsburgh, PA, USA

*Heather J. Zar, MD
Cape Town, South Africa

**Participants in Panel to develop the report. Also included was Peter D. Sly MD, Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, Perth, Western Australia, Australia.*

Reviewers

Hans Bisgaard, MD, DMSci
Copenhagen, Denmark

Jacque de Blic, MD
Paris, France

Johan De Jongste, MD
Rotterdam, The Netherlands.

Renato Stein, MD
Rio Grande do Sul, Brazil

Stan Szeffler, MD
Denver, CO, USA

Göran Wennergren, MD
Göteborg, Sweden

GINA Assembly Members Submitting Comments

Carlos E. Baena-Cagnani, MD
Cordoba, Argentina

Chunxue Bai, MD, PhD
Shanghai, China

Hisbello da Silva Campos, MD
Rio De Janeiro, RJ Brazil

Motohiro Ebisawa, MD, Ph.D
Kanagawa, Japan

Aziz Koleilat, MD
Beirut, Lebanon

Le Thi Tuyet Lan, MD, PhD
Ho Chi Minh City, Viet Nam

Sohei Makino, MD
Shigemi Yoshihara, MD
Dokkyo, Japan

Eva Mantzouranis, MD
Heraklion, Crete, Greece

Patrick Manning, MD
Dublin, Ireland

Yousser Mohammad, MD
Gazal Dib, MD
Samira Mohammad, MD
Fatmeh Dmeiraoui, MD
Lattakia, Syria

Hugo E. Neffen, MD
Santa Fe, Argentina

Lexley M Pinto Pereira, MBBS, MD
Trinidad, West Indies

Petr Pohunek, MD
Czech Republic

Young Soo Shim, MD
Seoul, Korea

Haluk Turktas, MD
Bulent Karadag, MD
Bulent Sekerel, MD
Hasan Yuksel, MD
Ankara, İstanbul, Manisa, Turkey

Chen Yu Zhi, MD
Beijing, P.R.China

Global Strategy for Asthma Management and Prevention in Children 5 Years and Younger

TABLE OF CONTENTS

PREFACE	iv	Pharmacotherapy	5
INTRODUCTION	1	<i>Table 3: Choosing an Inhaler Device for Children with Asthma</i>	6
I. RISK FACTORS ASSOCIATED WITH DEVELOPMENT OF ASTHMA	1	Controller Medications	7
Aeroallergens	1	Comparisons Between Controller Medications	8
House Dust Mites	1	Reliever Medications	8
Companion animal allergens	1	Treatment Strategy	8
Cockroaches	1	Who Should be Treated	8
Fungi	1	Selecting Initial Therapy	8
Maternal Dietary Avoidance During Pregnancy and/or Lactation	1	<i>Table 4: Low Daily Doses of Inhaled Glucocorticosteroids for Children 5 Years and Younger</i>	8
Pollutants	2	<i>Table 5: Asthma Management Approach Based on Control for Children 5 Years and Younger</i>	9
Microbes and Their Products	2	When Control is not Achieved	9
Psychosocial Factors	2	Duration and Adjustments to Treatment	9
Other Risk Factors	2	Approach to the Child with Intermittent Wheezing Episodes	9
Summary	2	Acute Exacerbations	10
II. DIAGNOSIS	2	Definition	10
Symptoms	3	Home Action Plan for Family/Caregivers	10
Wheeze	3	Assessment of Severity	11
Cough	3	<i>Table 6: Initial Assessment of Acute Asthma in Children 5 Years and Younger</i>	11
Breathlessness	3	Indications for Hospitalization	11
Clinical History	3	<i>Table 7: Indications for Immediate Referral to Hospital (if any of the following are present)</i>	11
Tests for Diagnosis and Monitoring	3	Emergency Treatment and Pharmacotherapy	12
Therapeutic Trial	3	Assessment of Treatment Response	12
Test for Atopy	3	Additional Treatment	12
Chest Radiography (x-ray)	3	Follow-up of Exacerbations	13
Differential Diagnosis	4	<i>Table 8: Initial Management of Acute Asthma in Children 5 Years and Younger</i>	13
<i>Table 1: Differential Diagnosis of Asthma in Children 5 Years and Younger</i>	4	IV. SUMMARY: KEY MESSAGES	14
Wheezing Phenotypes	4	V. REFERENCES	15
III. MANAGEMENT AND PHARMACOLOGIC TREATMENT	4		
Asthma Education	5		
Asthma Control	5		
<i>Table 2. Levels of Asthma Control in Children 5 Years and Younger</i>	6		

PREFACE

Each year, the Global Initiative for Asthma (GINA) updates its guidelines for treatment of asthma, the *Global Strategy for Asthma Management and Prevention*, and makes it available via the GINA Website at www.ginasthma.org. That guideline document provides a unified text and a source document for other GINA documents and resources. Each chapter contains, where relevant, details and management advice for specific age groups including children 5 years and younger, children older than 5 years, adolescents, adults, and the elderly. Most of the differences between these age groups relate to natural history and co-morbidities, but there are also important differences in the approach to diagnosis, measures for assessing severity and monitoring control, responses to different classes of medications, techniques for engaging with the patient and his/her family in establishing and maintaining a treatment plan, and the psychosocial challenges presented at different stages of life.

In January 2008, the GINA Executive Committee convened a panel of pediatric experts* to prepare a conceptual framework for the diagnosis and management of asthma in children 5 years and younger. In this report, *Global Strategy for Asthma Management and Prevention in Children 5 Years and Younger*, an effort has been made to present the special challenges that must be taken into account in managing asthma in children during the first 5 years of life, including difficulties with diagnosis, the efficacy and safety of drugs and drug delivery systems, and the lack of data on new therapies. Approaches to these issues will vary among populations in the world based on socioeconomic conditions, genetic diversity, cultural beliefs, and differences in health care access and delivery. Patients in this age group are often managed by pediatricians and general practitioners who are routinely faced with a wide variety of issues related to childhood diseases. While this report highlights a number of issues specific to the under-5 age group, the reader is referred to the *Global Strategy for Asthma Management and Prevention* for fuller background on asthma pathology, pathophysiology, and medications.

Recommendations in this report are made based on the best evidence currently available, and are intended to serve as an initial reference point with the recognition that some recommendations may need to be modified to adapt to the population characteristics and health care resources present in different clinical practice settings.

The panel was charged with the responsibility of reviewing the available scientific literature and assigning evidence levels (A,

B, C, and D) according to the methodology used in previous GINA documents¹ (Table A). Because of the relative paucity of randomized clinical trials in children 5 years and younger, many of the recommendations are identified as **Evidence D**, expert opinion. However, in many of these cases, the expert opinion is based on randomized clinical trial data from studies conducted in older children and adults. The GINA Executive Committee is aware of the trend toward application of GRADE² technology and is developing a system to slowly make a transition to this methodology.



Eric Bateman, MD
Chair, GINA Executive Committee

Table A. Description of Levels of Evidence

Evidence Category	Sources of Evidence	Definition
A	Randomized controlled trials (RCTs). Rich body of data.	Evidence is from endpoints of well designed RCTs that provide a consistent pattern of findings in the population for which the recommendation is made. Category A requires substantial numbers of studies involving substantial numbers of participants.
B	Randomized controlled trials (RCTs). Limited body of data.	Evidence is from endpoints of intervention studies that include only a limited number of patients, posthoc or subgroup analysis of RCTs, or meta-analysis of RCTs. In general, Category B pertains when few randomized trials exist, they are small in size, they were undertaken in a population that differs from the target population of the recommendation, or the results are somewhat inconsistent.
C	Nonrandomized trials. Observational studies.	Evidence is from outcomes of uncontrolled or nonrandomized trials or from observational studies.
D	Panel consensus judgment.	This category is used only in cases where the provision of some guidance was deemed valuable but the clinical literature addressing the subject was insufficient to justify placement in one of the other categories. The Panel Consensus is based on clinical experience or knowledge that does not meet the above-listed criteria.

INTRODUCTION

Asthma is the most common chronic disease of childhood and the leading cause of childhood morbidity from chronic disease as measured by school absences, emergency department visits, and hospitalizations³. Asthma typically begins in early childhood, with an earlier onset in males than females^{4,6}. Atopy is present in the majority of children with asthma over the age of 3, and allergen-specific sensitization is one of the most important risk factors for the development of asthma⁷. However, no intervention has yet been shown to prevent the development of asthma or to modify the long-term natural course of the disease⁸⁻¹⁶ (**Evidence A**).

Asthma is defined as a chronic inflammatory disorder of the airways and is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing¹. However, in children 5 years and younger, the clinical symptoms of asthma are variable and non-specific. Furthermore, neither airflow limitation nor airway inflammation, the main pathologic hallmarks of the condition, can be assessed routinely in this age group. For this reason, to aid in the diagnosis of asthma in young children, a symptoms-only descriptive approach that includes the definition of various wheezing phenotypes has been recommended¹⁷.

For all patients with a confirmed diagnosis of asthma, the goal of treatment is to achieve control of the clinical manifestations of the disease, and maintain this control for prolonged periods, with appropriate regard to the safety and cost of the treatment required to achieve this goal. Control of asthma can be achieved in a majority of children 5 years and younger with a pharmacologic intervention strategy developed in partnership between the family/caregiver and the health care practitioner. As in older children and adults, inhaled therapy constitutes the cornerstone of asthma treatment in children 5 years and younger.

I. RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF ASTHMA

Epidemiologic studies have identified a number of risk factors associated with the development of asthma, including (but not limited to) sensitization to aeroallergens, maternal diet

during pregnancy and/or lactation, pollutants (particularly environmental tobacco smoke), microbes and their products, and psychosocial factors. However, evidence for avoidance measures to prevent asthma is lacking in many cases.

AEROALLERGENS

Atopic sensitization to common aeroallergens, especially perennial inhalant allergens, is an important risk factor associated with asthma¹⁸. For some children, the earlier in life they become sensitized to local allergens the greater their risk for asthma later in life⁷, especially when sensitization occurs in association with frequent lower respiratory illnesses⁸. Several types of aeroallergens are particularly important in relation to asthma.

House Dust Mites: A Cochrane analysis questioned the effectiveness of house dust mite avoidance for the treatment of established asthma⁹. Moreover, there is no evidence that anti-house dust mite measures prevent the onset of asthma¹⁰⁻¹².

Companion Animal Allergens: The relationship between exposure and sensitization to allergens from companion animals is not clear, and there are insufficient data to recommend for, or against, the presence of a pet in the home unless the child has become sensitized to the pet species^{13-15, 18}.

Cockroaches: Exposure to cockroach allergen in the living quarters is associated with the development of sensitization, and sensitization to cockroach allergen is associated with an increased risk of developing asthma¹⁶.

Fungi: Sensitization to *Alternaria* is a major risk factor not only for the development of asthma in children, but also for its severity^{19,20}. *Alternaria* is usually considered an outdoor aeroallergen, but outdoor and indoor concentrations may be similar²¹.

MATERNAL DIET DURING PREGNANCY AND/OR LACTATION

At present, there are insufficient data to support a protective effect of any dietary intervention during pregnancy or lactation in preventing asthma or atopic disease^{22,23}. Breastfeeding itself decreases early childhood wheezing syndromes associated with upper and lower respiratory infections. However, although recommended for its general health benefits, there is little evidence that breastfeeding prevents development of persistent asthma^{8, 24-26}.

POLLUTANTS

Maternal smoking during pregnancy and exposure to environmental tobacco smoke early in life are associated with a greater risk of developing wheezing illnesses in childhood²⁷, as well as with reduced lung function later in life⁶. Therefore, every effort should be made to avoid exposing children to tobacco smoke²⁸.

Use of biomass fuels in the home has been associated with an increased risk of asthma, increased severity of asthma, and exercise-induced bronchospasm in children^{29,30}. This presents a problem in much of the world where biomass fuels such as wood, charcoal, animal dung, and crop residues are used on a daily basis for cooking and/or heating. Outdoor air pollution related to traffic has been shown to trigger wheezing in the first 3 years of life³¹.

MICROBES AND THEIR PRODUCTS

Wheezing in early childhood is predominately linked to viral infections, especially those due to rhinovirus, respiratory syncytial virus (RSV), Boca virus, and metapneumovirus (MPV)^{32,34}.

The impact of bacterial products and their relationship to the development of asthma is increasingly a focus of interest and forms part of the so-called "hygiene hypothesis." Exposure to a farming environment in early life has been associated with a reduced risk of asthma and allergy in children compared to those who have not grown up on a farm^{35,36}. In this regard, exposure to the lipopolysaccharide endotoxin from microorganisms encountered in the farming environment appears to be a potential protective factor, particularly in children with specific genetic polymorphisms³⁷.

Since intestinal flora are the largest source of microbial exposure for most infants and children, the use of probiotics to modify the composition of intestinal flora has been proposed as a method for exploiting this asthma-protective effect of microbes. While probiotics have been shown to be of some benefit in the prevention of atopic dermatitis, no impact on the development of asthma has been demonstrated³⁸.

Although the use of antibiotics also modifies the composition of intestinal flora, the impact of use of antibiotics early in life on the risk of developing asthma later in life is controversial^{39,40}. Based on available data, it is recommended that particularly broad-spectrum antibiotics should be used with circumspection in this young age group, and only for recognized indications (Evidence D).

PSYCHOSOCIAL FACTORS

A child's social environment may play a role in the development and severity of asthma^{41,42}. Stress in family or other primary caregivers during the first year of life is associated with an atopic profile and wheeze in infants, and is also associated with asthma at age 6 to 8 years⁴³. Maternal distress in early life may play a role in the development of childhood asthma, especially if the distress continues beyond the postpartum period⁴⁴.

OTHER RISK FACTORS

Children born by Cesarean section have a higher risk of asthma than those born by vaginal delivery⁴⁵, particularly children of allergic parents⁴⁶. Paracetamol (acetaminophen) use during pregnancy⁴⁷ and for fever in the child's first year of life⁴⁸ have been associated with increased prevalence of asthma in children.

SUMMARY

Since the contributions of different risk factors to the development of asthma vary widely in different societies and homes, their relative importance overall may be difficult to assess. Avoidance of some risk factors requires societal and public health interventions. However, measures to avoid other risk factors can be implemented by individual concerned parents as part of their personal preventive strategies for asthma, and these include:

- Avoid exposures to atmospheric pollution and particularly tobacco smoke
- Avoid unnecessary use of antibiotics in young children
- Provide a calm and nurturing environment (Evidence D).

II. DIAGNOSIS

Making a diagnosis of asthma in children 5 years and younger may be difficult because episodic respiratory symptoms such as wheezing and cough are also common in children who do not have asthma, particularly in those younger than 3 years^{49,50}. Furthermore, it is not possible to routinely assess both airflow limitation and inflammation in this age group. Nevertheless, a diagnosis of asthma in young children can often be made based largely on symptom patterns and on a careful clinical assessment of family history and physical findings. The presence of atopy or allergic sensitization provides additional predictive support, as early allergic sensitization increases the likelihood that a wheezing child will have asthma⁷.

SYMPTOMS

Symptoms in this age group that may indicate a diagnosis of asthma include wheeze, cough, breathlessness (typically manifested by patterns of activity limitation), and nocturnal symptoms/awakenings.

Wheeze: Wheeze, the most common symptom associated with asthma in children 5 years and younger, has been strictly defined as a continuous high-pitched sound, sometimes with musical quality, emitting from the chest during expiration⁵¹. Wheezing occurs in several different patterns but a wheeze that occurs recurrently, during sleep, or with triggers such as activity, laughing, or crying is consistent with a diagnosis of asthma.

Wheezing may be interpreted differently based on the individual observing it (e.g., parent versus clinician), when it is being reported (e.g., retrospectively versus in real time), the environmental context in which it is occurring (e.g., wheeze may have different presentation patterns in areas of the world where parasites with life cycles involving the lung are more prevalent), and the cultural context in which it is occurring (e.g., different cultures assign different relative importance to certain symptoms and to diagnosis and treatment of respiratory tract diseases in general).

Viral respiratory infections are the most common factors responsible for acute wheezing episodes in young children, and some viral infections (RSV and rhinovirus) are associated with recurrent wheeze throughout childhood. Since many young children may wheeze with viral infections, deciding when the presence of wheezing with infections is truly an initial or recurrent clinical presentation of childhood asthma is difficult⁵.

Cough: Cough due to asthma is recurrent and/or persistent, and is usually accompanied by some wheezing episodes and breathing difficulties. Nocturnal cough (occurring when the child is asleep) or cough occurring with exercise, laughing, or crying in the absence of an apparent respiratory infection, strongly supports a diagnosis of asthma. The common cold and other respiratory illnesses are also associated with cough.

Breathlessness (Terms often used by parents include difficult breathing, heavy breathing, and shortness of breath): Breathlessness that occurs during exercise and is recurrent increases the likelihood of the presentation being due to asthma. In infants and toddlers, crying and laughing are an exercise equivalent.

CLINICAL HISTORY

For children 5 years and younger with a history of recurrent respiratory symptoms; a strong family history of asthma in first degree relatives (especially the mother); and/or atopy presenting as atopic dermatitis, food allergy, and/or allergic rhinitis also make a diagnosis of asthma more likely.

TESTS FOR DIAGNOSIS AND MONITORING

While no tests diagnose asthma with certainty in young children, the following may be considered as useful adjuncts in making a diagnostic decision.

Therapeutic Trial: A trial of treatment with short-acting bronchodilators and inhaled glucocorticosteroids for at least 8 to 12 weeks may provide some guidance as to the presence of asthma (**Evidence D**). These interventions should be evaluated in terms of how they affect control of daytime and nocturnal symptoms as well as the frequency of exacerbations requiring increasing doses of inhaled or systemic glucocorticosteroids. Marked clinical improvement during the treatment and deterioration when it is stopped supports a diagnosis of asthma. Due to the variable nature of asthma in young children, a therapeutic trial may need to be repeated more than once in order to be certain of the diagnosis.

Tests for Atopy: Sensitization to allergens can be assessed using either immediate hypersensitivity skin testing or an in vitro method that detects antigen-specific IgE antibody. Skin-prick testing is less reliable for confirming atopy in infants.

Chest Radiograph (X-ray): If there is doubt about the diagnosis of asthma in a wheezing child, a plain chest radiograph may help to exclude structural abnormalities of the airway (e.g., congenital malformations such as congenital lobar emphysema, vascular ring), chronic infection (e.g. tuberculosis), or other diagnoses.

Lung function testing, bronchial challenge, and other physiological tests do not have a major role in the diagnosis of asthma in children 5 years and younger due to the inability of children this age to perform reproducible expiratory maneuvers. Such tests are only possible in specialized centers, and are undertaken mainly for research purposes.

DIFFERENTIAL DIAGNOSIS

Although a variety of tools have been described above to aid the clinician in making a diagnosis of asthma in children 5 years and younger, it must be emphasized that a definite diagnosis in this young age group is challenging and has important clinical consequences. Thus, alternative causes that can lead to respiratory symptoms of wheeze, cough, and breathlessness must be considered and excluded before an asthma diagnosis is arrived at⁴⁹ (Table 1).

TABLE 1: Differential Diagnosis of Asthma in Children 5 Years and Younger

Infections

- Recurrent respiratory tract infections
- Chronic rhino-sinusitis
- Tuberculosis

Congenital problems

- Tracheomalacia
- Cystic fibrosis
- Bronchopulmonary dysplasia
- Congenital malformation causing narrowing of the intrathoracic airways
- Primary ciliary dyskinesia syndrome
- Immune deficiency
- Congenital heart disease

Mechanical problems

- Foreign body aspiration
- Gastroesophageal reflux

Neonatal or very early onset of symptoms (associated with failure to thrive), symptoms associated with vomiting, or focal lung or cardiovascular signs, suggest an alternative diagnosis and indicate the need for further investigations.

WHEEZING PHENOTYPES

Recurrent wheezing occurs in a large proportion of children five years and younger. However, not all of this wheezing indicates asthma. Several phenotypes of wheezing disorders in this age group have been recognized in epidemiologic studies.

Early childhood wheezing has been classified by a Task Group convened by the European Respiratory Society (ERS)¹⁷ as either episodic wheeze (wheezing during discrete time periods, often in association with clinical evidence of a common cold, with absence of wheeze between episodes) or multiple-trigger wheeze (wheezing that occurs as episodic exacerbations as above, but also with symptoms including cough and wheeze occurring between these episodes, during sleep or with triggers such as activity, laughing, or crying).

Data from a U.S. cohort study⁶ led to the description of three wheezing phenotypes: transient wheeze (symptoms begin and end before the age of 3 years), persistent wheeze (symptoms begin before the age of 3 years and continue beyond the age of 6 years), and late-onset wheeze (symptoms begin after the age of 3 years).

The clinical usefulness of the phenotypes described by the ERS Task Group¹⁷ or based on data from the U.S. cohort study⁶ remains a subject of active investigation. Children with asthma may have any of these phenotypes, but asthma occurs much more rarely in the episodic wheeze and transient wheeze phenotypes compared to the other phenotypes. A number of other publications provide additional insights into wheezing phenotypes and their relationship to children 5 years and younger with asthma^{6,52,53}.

To aid in the early identification, in the clinical setting, of children 5 years and younger who wheeze and are at high risk of developing persistent asthma symptoms, a number of risk profiles have been evaluated^{54,57}. One such predictive assessment, the Asthma Predictive Index (API), is recommended for children with four or more wheezing episodes in a year and is based on information obtained from the Tucson (USA) Respiratory Study⁵⁵. One study has shown that a child with a positive API has a 4- to 10- fold greater chance of developing asthma between the ages of 6 and 13, while 95% of children with a negative API remained free of asthma^{55,57} (Evidence C). The applicability and validation of the API in other countries and clinical situations is awaited.

III. MANAGEMENT AND PHARMACOLOGIC CONTROL

For all patients with a confirmed diagnosis of asthma, the goal of treatment is to achieve control of the clinical manifestations of the disease, and maintain this control for prolonged periods, with appropriate regard to the safety and cost of the treatment required to achieve this goal. Control of asthma can be achieved in a majority of children 5 years and younger with a pharmacologic intervention strategy developed in partnership between the family/caregiver and the health care practitioner. As in older children and adults, inhaled therapy constitutes the cornerstone of asthma treatment in children 5 years and younger (Evidence A).

ASTHMA EDUCATION

Asthma education should be provided to family members and caregivers of wheezy children 5 years and younger when wheeze is suspected to be caused by asthma (**Evidence D**). An educational package should contain a basic explanation about asthma and the factors that influence it, instruction about correct inhalation technique and the importance of adherence to the prescribed medication regime, and a description of how to recognize when asthma control is deteriorating, the medications to administer when this occurs, and when to seek medical assistance. Randomized controlled trials in older children and adults have demonstrated that the use of a written asthma management plan along with careful verbal explanation of the treatment regime can improve asthma control. For children 5 years and younger who cannot reliably perform lung function measurements, asthma management plans based on the levels of respiratory symptoms have been shown to be just as effective as plans based on self-monitoring of lung function⁵⁸ (**Evidence B**). Crucial to a successful asthma education program are a **patient-doctor partnership** featuring a high level of agreement between family or caregiver and healthcare practitioner regarding the goals of treatment for the child, as well as **intensive follow-up**⁵⁹ (**Evidence D**).

ASTHMA CONTROL

For all patients with a confirmed diagnosis of asthma, the goal of treatment is to achieve control of the clinical manifestations of the disease and maintain this control for prolonged periods, with appropriate regard to the safety and cost of the treatment required to achieve this goal.

The relevance of distinguishing between current control (as assessed by the control or elimination of clinical features of asthma in the recent weeks or months) from “future risk” (the likelihood of future worsening, exacerbations, impaired lung development), and the relationship between these two concepts, have not been carefully studied in small children. However, a combination of increased daytime cough, daytime wheeze, and nighttime β_2 -agonist use has been found to be a strong predictor of an exacerbation in children 5 years and younger (predicting around 70% of exacerbations, with a low false positive rate of 14%⁶⁰). In contrast, no individual symptom was predictive of an imminent asthma exacerbation. This finding indirectly supports the importance of good daily asthma control and the use of composite outcomes in the assessment of asthma control in this age group.

Although exacerbations may occur in children after months of apparent clinical control, the risk is greater in patients whose current control is poor. On the other hand, the “future risk” of harm caused by excessive doses of medications, or inappropriate treatment such as the prolonged use of high doses of inhaled or systemic glucocorticosteroids, must also be avoided by ensuring that treatment is appropriate and reduced to the lowest level that maintains satisfactory current clinical control.

Defining satisfactory current clinical asthma control in children 5 years and younger is problematic, since health care providers are almost exclusively dependent on the reports of the child’s family members and caregivers who might be unaware either of the presence of asthma symptoms, or of the fact that they represent uncontrolled asthma. Moreover, as with the diagnosis of asthma, lung function testing is not feasible as a means to monitor control in children of this age. No objective measures to assess clinical control have been validated for children younger than 4 years (one such measure has been developed for children aged 4–11⁶¹). However, a working scheme based on current expert opinion presents characteristics of controlled, partly controlled, and uncontrolled asthma for children 5 years and younger based on symptoms recognized by family members/caregivers and the child’s need for reliever/rescue treatment (Table 2) (**Evidence D**).

PHARMACOTHERAPY

Inhaled therapy constitutes the cornerstone of asthma treatment in children 5 years and younger. A general strategy for choosing inhalers in children is provided in Table 3. A pressurized metered-dose inhaler (MDI) with a valved spacer (with or without a face mask, depending on the child’s age) is the preferred delivery system⁶² (**Evidence A**). This recommendation is based on studies with performed with β_2 -agonists.

Spacers come in different designs and, since the dose received may vary considerably from one device to another, a spacer device that has documented efficacy in young children is recommended. Nebulizers, the only viable alternative delivery systems in children, should be reserved for the minority of children who cannot be taught effective use of a spacer device.

Table 2. Levels of Asthma Control in Children 5 Years and Younger*

Characteristic	Controlled (All of the following)	Partly Controlled (Any measure present in any week)	Uncontrolled (3 or more of features of partly controlled asthma in any week)
Daytime symptoms: wheezing, cough, difficult breathing	None (less than twice/week, typically for short periods on the order of minutes and rapidly relieved by use of a rapid-acting bronchodilator)	More than twice/week (typically for short periods on the order of minutes and rapidly relieved by use of a rapid-acting bronchodilator)	More than twice/week (typically last minutes or hours or recur, but partially or fully relieved with rapid-acting bronchodilator)
Limitations of activities	None (child is fully active, plays and runs without limitation or symptoms)	Any (may cough, wheeze, or have difficulty breathing during exercise, vigorous play, or laughing)	Any (may cough, wheeze, or have difficulty breathing during exercise, vigorous play, or laughing)
Nocturnal symptoms/awakening	None (including no nocturnal coughing during sleep)	Any (typically coughs during sleep or wakes with cough, wheezing, and/or difficult breathing)	Any (typically coughs during sleep or wakes with cough, wheezing, and/or difficult breathing)
Need for reliever/rescue treatment	" 2 days/week	> 2 days/week	> 2 days/week

*Any exacerbation should prompt review of maintenance treatment to ensure that it is adequate. Although patients with current clinical control are less likely to experience exacerbations, they are still at risk during viral upper respiratory tract infections and may still have one or more exacerbations per year.

Table 3: Choosing an Inhaler Device for Children with Asthma

Age Group	Preferred Device	Alternative Device
Younger than 4 years	Pressurized metered-dose inhaler <i>plus</i> dedicated spacer with face mask	Nebulizer with face mask
4-5 years	Pressurized metered-dose inhaler <i>plus</i> dedicated spacer with mouthpiece	Pressurized metered-dose inhaler <i>plus</i> dedicated spacer with face mask, or Nebulizer with mouthpiece or face mask

Controlled trials in children 5 years and younger are rather limited, the patient populations have often not been well characterized with respect to phenotype (including wheezy children who may or may not have asthma), and different studies have used different outcomes and definitions of exacerbations. However, based on literature that is available, extrapolations

from studies in older children and adults, and on expert opinion, the following sections provide recommendations for controller medications (taken daily on a long-term basis to keep asthma under control) and reliever medications (for use on an as-needed basis) for the pharmacologic treatment of asthma in children 5 years and younger.

Controller Medications

Inhaled glucocorticosteroids

Efficacy: As in older children, several placebo-controlled studies of inhaled glucocorticosteroids in children 5 years and younger with asthma have found statistically significant clinical effects on a variety of outcomes, including increased lung function and number of symptom-free days, and reduced symptoms, need for additional medication, caregiver burden, systemic glucocorticosteroid use, and exacerbations^{57,63-73} (**Evidence A**). However, the dose-response relationships have been less well studied. The clinical response may differ depending on the specific device used for delivery and the child's ability to use it correctly. With correct use of a spacer device, twice the recommended initial low dose of inhaled glucocorticosteroid results in near-maximum benefits as regular, long-term treatment in the majority of patients (**Table 4**)^{64,68}. Use of inhaled glucocorticosteroids for up to 2 years has not been documented to induce remission of asthma; symptoms almost always return when treatment is stopped⁵⁷ (**Evidence B**).

Safety: The majority of studies evaluating the systemic effects of inhaled glucocorticosteroids have been undertaken in children older than 5 years. However, the available data in children 5 years and younger suggest that, as in older children, clinically effective doses of inhaled glucocorticosteroids are safe and the potential risks are well balanced by the clinical benefits^{57,63,73}. Generally, low doses of inhaled glucocorticosteroids (**Table 4**) have not been associated with any clinically serious adverse systemic effects in clinical trials and are considered safe^{63,73} (**Evidence A**). However, higher doses have been associated with detectable systemic effects on both growth and the hypothalamic-pituitary-adrenal (HPA) axis^{57,63,73}. These effects are similar to those reported in studies of older children, which find no evidence of long-term clinical impact^{74,75}. Local side effects, such as hoarseness and candidiasis, are rare in children 5 years and younger⁶⁸.

Leukotriene modifiers

Efficacy: Leukotriene modifiers reduce viral-induced asthma symptoms in children ages 2-5 years with a history of intermittent asthma⁷⁶ by reducing the number of protocol-defined exacerbations, but do not reduce the frequency of hospitalizations, use of prednisolone, duration of exacerbations, or days without asthma symptoms. Moreover, no effect on post-bronchiolitic wheeze or cough is seen following hospitalization with RSV bronchiolitis⁷⁷. In a three-month study of children with persistent wheeze, montelukast reduced symptoms and rescue β_2 -agonist use by approximately 6%. The per-

centage of patients experiencing an asthma attack was not significantly reduced, but the need for a course of prednisolone was significantly reduced from 28% to 19% of patients⁷⁸. Montelukast has also been shown to reduce airway hyperresponsiveness to methacholine⁷⁶ or hyperventilation with cold dry air⁷⁹. A randomized, placebo-controlled trial of the addition of montelukast to usual asthma therapy among 42 children aged 2-5⁸⁰ found that this treatment reduced the number of days with worsening of asthma symptoms in boys but not in girls, the number of days with symptoms in the two groups being 7.8% and 3.5%, respectively. In summary, leukotriene modifiers improve some asthma outcomes in young children (**Evidence A**). However, the role of leukotriene modifiers as add-on therapy in children 5 years and younger whose asthma is uncontrolled on inhaled glucocorticosteroids has not been specifically evaluated.

Safety: No safety concerns have been demonstrated from the use of leukotriene modifiers in young children.

Theophylline

Although a few studies in children 5 years and younger suggest clinical benefit from regular use of theophylline, the effects are small and mostly non-significant⁸¹. The efficacy of theophylline is less than that of low-dose inhaled glucocorticosteroids, and side effects are more common (**Evidence D**).

Long-acting inhaled β_2 -agonists

Long-acting inhaled β_2 -agonists (LABAs) are bronchodilators, but as long-term therapy for asthma they are only prescribed in combination with an inhaled glucocorticosteroid and are therefore considered controller medications. The effect of long-acting inhaled β_2 -agonists or combination (LABA/glucocorticosteroid) products has not been adequately studied in children 5 years and younger. Formoterol and salmeterol have shown long-lasting bronchodilatory and bronchoprotective effects in this age group⁸². However, there are no published randomized placebo-controlled trials in this age group on the addition of long-acting inhaled β_2 -adrenergic agents to inhaled glucocorticosteroids. Therefore, long-acting inhaled β_2 -agonists cannot be recommended in this age group (**Evidence D**).

Cromolyn and nedocromil sodium

A Cochrane Review concluded that there was no beneficial effect of cromolyn therapy in preschool children^{83,84} and nedocromil has not been studied in preschool children. Therefore, cromones cannot be recommended in this age group (**Evidence A**).

Oral and systemic glucocorticosteroids

Because of the side effects associated with prolonged use, oral glucocorticosteroids in young children with asthma should be restricted to the treatment of acute severe exacerbations, whether viral-induced or otherwise (Evidence D).

Immunotherapy

No studies of immunotherapy for asthma have been performed in this age group. Therefore, immunotherapy is not recommended for the treatment or prophylaxis of asthma in children 5 years and younger (Evidence D).

Comparisons Between Controller Medications

In older children and adults, regular treatment with inhaled glucocorticosteroids has been well documented to be clinically more effective than other controller treatments for asthma. Moreover, they attenuate the decline in lung function seen in association with severe exacerbations⁸⁵. Fewer comparative studies have been conducted in children 5 years and younger. However, two studies of nearly 1,000 children in this age group^{86,87} confirmed the superiority of inhaled glucocorticosteroids over cromones for almost all endpoints assessing asthma control (Evidence A).

Two additional studies compared inhaled glucocorticosteroids with leukotriene modifiers. A one-year, randomized, open study compared montelukast with nebulized budesonide in 400 children; overall measures favored budesonide⁸⁸. In the second, a blinded, placebo-controlled study of 63 children, only the fluticasone propionate treatment significantly improved symptoms over placebo, whereas montelukast did not, and fluticasone propionate also improved lung function after three months⁸⁹ (Evidence B).

Reliever Medications

Rapid-acting inhaled β_2 -agonists are the most effective bronchodilators available and therefore the preferred reliever treatment for asthma in children 5 years and younger. An MDI with spacer is, in most cases, an effective way for delivering reliever therapy^{62,90} (Evidence A). When delivery is not optimal because of lack of cooperation or distress, or when the child is hypoxic, nebulizer therapy is also an option. Oral therapy is not recommended due to its slower onset of action and its tendency to produce more side effects.

There is no evidence that inhaled ipratropium has an important role in the daily management of asthma in children 5 years and younger⁹¹ (Evidence A).

TREATMENT STRATEGY

The goal of asthma treatment, to achieve and maintain control of the disease, can be reached in a majority of children 5 years and younger with a pharmacologic intervention strategy⁸⁶ developed in partnership between the family/caregiver and the health care practitioner. Although validated tools for assessment of asthma control have not been developed for young children, it is recommended that both current impairment (day and night symptoms, activity level impairment, need for rescue medications) and future risk (likelihood of acute exacerbation in the future) be assessed and controlled (Table 2) (Evidence B).

Who Should be Treated

Regular controller treatment is normally recommended for children 5 years and younger whose frequency and severity of asthma symptoms without treatment indicates that their asthma is not controlled (Table 2).

Selecting Initial Therapy

A low-dose inhaled glucocorticosteroid is recommended as the preferred initial treatment to control asthma in children 5 years and younger^{57,70,88} (Table 4) (Evidence A).

Table 4: Low Daily Doses* of Inhaled Glucocorticosteroids for Children 5 Years and Younger	
Drug	Low Daily Dose (μ g)
Beclomethasone dipropionate	100
Budesonide MDI+spacer Budesonide nebulized	200 500
[†] Ciclesonide	NS
Fluticasone propionate	100
[†] Mometasone furoate	NS
[†] Triamcinolone acetonide	NS

* A low daily dose is defined as the dose which has not been associated with clinically adverse effects in trials including measures of safety. This is not a table of clinical equivalence.

[†]NS = Not studied in this age group.

This initial treatment should be given for at least 3 months to establish its effectiveness in reaching control. If at the end of this period the low dose of inhaled glucocorticosteroid does not control symptoms, and the child is using optimal technique and is adherent to therapy, doubling the initial dose of glucocorticosteroid given in **Table 4** may be the best option⁶⁴ (**Evidence C**). Addition of a leukotriene modifier to the low-dose inhaled glucocorticosteroid may also be considered, although this has not been studied in this age group (**Evidence D**).

Table 5 presents a management approach based on asthma control for children 5 years and younger.

Table 5. Asthma Management Approach Based on Control for Children 5 Years and Younger		
Asthma education Environmental control As needed rapid-acting β_2 -agonists		
Controlled on as needed rapid-acting β_2 -agonists	Partly controlled on as needed rapid-acting β_2 -agonists	Uncontrolled or only partly controlled on low-dose inhaled glucocorticosteroid*
Controller options		
Continue as needed rapid-acting β_2 -agonists	Low-dose inhaled glucocorticosteroid	Double low-dose inhaled glucocorticosteroid
	Leukotriene modifier	Low-dose inhaled glucocorticosteroid plus leukotriene modifier

*Oral glucocorticosteroids should be used only for treatment of acute severe exacerbations of asthma.

Shaded boxes represent the preferred treatment options.

Clinicians should check local prescribing licenses for medication dosages.

When Control is not Achieved: When doubling the initial dose of inhaled glucocorticosteroids fails to achieve and maintain asthma control, the child's inhalation technique and compliance with the medication regimen should be carefully assessed and monitored, as these are common problems in this age group. Furthermore, control of environmental factors should be assessed and addressed appropriately, and the asthma diagnosis reconsidered.

The best treatment for children whose asthma is not controlled on twice the initial dose of inhaled glucocorticosteroid has not been established. Options to consider are to further increase the dose of inhaled glucocorticosteroid (perhaps combined with more frequent dosing), or to add a leukotriene modifier, theophylline, or a low dose of oral glucocorticosteroid for a few weeks until the control of the child's asthma improves (**Evidence D**). The need for this additional treatment should be re-evaluated at each visit and maintained for as short a period as possible. Furthermore, the treatment goal or level of control that is feasible for each child must be considered and discussed with the family/caregivers, since a compromise might be necessary—accepting a level of persisting symptoms to avoid excessive and harmful doses of oral and inhaled glucocorticosteroids or theophylline.

Duration and Adjustments to Treatment: Asthma symptoms remit in a substantial proportion of children 5 years and younger, and marked seasonal variations are seen in chronic symptoms and the risk of exacerbations. For children with seasonal symptoms, if daily long-term control therapy is discontinued after the season a written action plan detailing specific signs of worsening asthma, and therapeutic interventions that should be subsequently initiated, should be reviewed with the caregivers. It is recommended that the continued need for asthma treatment in children under age 5 should be regularly assessed (e.g., every three to six months) (**Evidence D**). A follow-up visit should be scheduled 3-6 weeks after discontinuation of therapy to ascertain whether the remission of symptoms persists and there is no need for reinstitution of therapy.

Approach to the Child with Intermittent Wheezing Episodes: Intermittent episodic wheezing of any severity may represent unrecognized uncontrolled asthma, an isolated viral-induced wheezing episode, or an episode of seasonal or allergen-induced asthma. The initial treatment is identical in any case: a dose of rapid-acting inhaled β_2 -agonist every 4–6 hours as needed for a day or more until symptoms disappear (**Evidence A**). However, uncertainty surrounds the addition of other drugs, especially when the nature of the episode is unclear.

If a detailed history suggests the diagnosis of asthma, and wheezing episodes are frequent (e.g., 3 in a season), regular controller treatment should be initiated (**Evidence D**). Regular controller treatment may also be indicated in a child with less frequent, but more severe, episodes of viral-induced wheeze (**Evidence D**).

Where the diagnosis is in doubt, and when rapid-acting inhaled β_2 -agonist therapy needs to be repeated more frequently than every 6-8 weeks, a diagnostic trial of regular controller therapy should be considered to confirm whether the symptoms are due to asthma (Evidence D).

The treatment of intermittent episodic wheezing that occurs in children where a diagnosis of asthma cannot be confirmed, or is unlikely, is controversial. The short-term addition of a controller medication—inhaled glucocorticosteroid, leukotriene modifier, or oral glucocorticosteroid—has demonstrated no effects on wheezing symptoms or progression to asthma⁹²⁻¹⁰⁰. However, in one study treating wheezing episodes with 1,500 μg of fluticasone propionate daily for 10 days reduced the need for oral glucocorticosteroids for the episode (18% in the untreated arm versus 8% in the treated arm)¹⁰¹. Therefore, although these treatments are widely practiced, based on current evidence, their continued use cannot be recommended (Evidence D).

ACUTE EXACERBATIONS

The management of acute exacerbations of asthma in children 5 years and younger includes an action plan to enable the child's family members and caregivers to recognize an asthma attack and initiate treatment, recognize a severe episode, identify when urgent hospitalized treatment is necessary, and provide specific recommendations for follow-up. (Evidence D).

Definition: An acute exacerbation of asthma in children 5 years and younger is defined as an acute or subacute deterioration in symptom control that is sufficient to cause distress or risk to health necessitating a visit to a health care provider or requiring treatment with systemic glucocorticosteroids¹⁰². Early symptoms of an acute exacerbation may include any of the following :

- An increase in wheeze and shortness of breath
- An increase in coughing, especially nocturnal cough
- Lethargy or reduced exercise tolerance
- Impairment of daily activities, including feeding
- A poor response to reliever medication

Upper respiratory symptoms frequently precede the onset of an asthma exacerbation, indicating the important role of upper respiratory tract viral infections in precipitating exacerbations in many, although not all, asthmatic children.

Home Action Plan for Family/Caregivers

An asthma action plan should be considered for use by the family/caregivers of children 5 years and younger (Evidence D). Developed through collaboration between an asthma educator, the health care provider, and the family, action plans have been shown to be of value in older children¹⁰³⁻¹⁰⁶, although they have not been sufficiently studied in this younger age group. An asthma action plan should contain details that will enable those who care for the child to recognize exacerbations early, and know what interventions are required, including when medical help should be sought. The home action plan should also provide details (including telephone numbers) of services available for emergencies – doctors' offices, emergency rooms and hospitals, ambulance services, and, where relevant, emergency pharmacies. Treatments that can be initiated at home are inhaled rapid-acting β_2 -agonist and oral glucocorticosteroids, but specific instructions on their use must be provided in the action plan.

Initial home management: Inhaled rapid-acting β_2 -agonist via a mask or spacer device and observation. Treatment should be initiated with two puffs (200 μg salbutamol or the equivalent) of inhaled rapid-acting β_2 -agonist, given one puff at a time via a mask or spacer device (Evidence D). The child should be observed by the family/caregiver and maintained in a restful and reassuring atmosphere for an hour or more. Medical attention should be sought the same day if the inhaled bronchodilator is required for symptom relief more than every 3 hours or for more than 24 hours.

Need for urgent medical attention.

Immediate medical attention should be sought:

- For children younger than 1 year requiring repeated rapid-acting inhaled β_2 -agonists over the course of hours
- If the child is acutely distressed
- If the symptoms are not relieved promptly by inhaled bronchodilator
- If the period of relief after a dose of inhaled β_2 -agonist becomes progressively shorter¹⁰⁷

Family/Caregiver Initiated Oral Glucocorticosteroids.

Although practiced in some parts of the world, the evidence to support the initiation of oral glucocorticosteroid treatment by family/caregivers in the home management of asthma exacerbations in children is weak, and should be considered only where the physician is confident that they will be used appropriately (Evidence D).

Assessment of Severity

Features that indicate that an exacerbation is severe are provided in **Table 6** and the presence of any of these features is an indication of the need for urgent treatment (**Evidence A**). Agitation, drowsiness, and confusion are features of cerebral hypoxemia. Percutaneous oxygen saturation of 92% or less on presentation (before oxygen or bronchodilator treatment) is associated with higher morbidity and greater likelihood of the need for hospitalization. Other clinical features of a severe attack requiring immediate treatment are inability to talk in sentences or phrases, tachycardia (200 beats per minute or more for children 0-3 years, and 180 beats per minute or more for children 4-5 years), central cyanosis, and a quiet chest on auscultation (indicating minimal ventilation – insufficient to produce a wheeze).

Indications for Hospitalization

Indications for hospitalization of children 5 years and younger are presented in **Table 7**. Children with features of a severe exacerbation that fail to resolve in 1 to 2 hours in spite of repeated dosing with rapid-acting inhaled β_2 -agonists, with or without the addition of oral glucocorticosteroids, must be referred for observation and further treatment in the hospital (**Evidence D**). Other indications are respiratory arrest or impending arrest, lack of supervision in the home or rooms, and recurrence of signs of severity within 48 hours of the initial exacerbation (particularly if treatment with systemic glucocorticosteroids has been given). In addition, early medical attention should be sought in children under 2 years of age where the risk of dehydration and respiratory fatigue is increased.

Symptoms	Mild	Severe ^a
Altered consciousness	No	Agitated, confused or drowsy
Oximetry on presentation ^b (SaO ₂)	≥ 94%	< 90%
Talks in sentences/words ^c	Sentences	Words
Pulse rate	< 100 bpm ^d	> 200 bpm (0-3 years) > 180 bpm (4-5 years)
Central cyanosis	Absent	Likely to be present
Wheeze intensity	Variable	May be quiet

^a Any of these features indicates a severe asthma exacerbation

^b Oximetry performed before treatment with oxygen or bronchodilator

^c The normal developmental capability of the child must be taken into account.

^d bpm = beats per minute.

<p>ANY of the following:</p> <ul style="list-style-type: none"> No response to three (3) administrations of an inhaled short-acting β_2-agonist within 1-2 hours Tachypnea despite 3 administrations of an inhaled short-acting β_2-agonist (Normal respiratory rate < 60 breaths per minute in children 0 – 2 months; < 50 in children 2 –12 months; < 40 in children 1 – 5 years) Child is unable to speak or drink or is breathless Cyanosis Subcostal retractions Oxygen saturation when breathing room air < 92% Social environment that impairs delivery of acute treatment; caregivers unable to manage acute asthma at home

Emergency Treatment and Pharmacotherapy

Treat hypoxemia: The presence of hypoxemia must be treated urgently with oxygen delivered by face mask, to achieve and maintain percutaneous oxygen saturation above 94% (**Evidence A**). A 24% facemask is usually adequate with oxygen flow set to manufacturer's instructions (usually 4 L per minute). To avoid hypoxemia during changes in treatment, children who are acutely distressed should be treated immediately with oxygen and rapid-acting bronchodilator (2.5 mg of salbutamol or equivalent diluted in 3 ml of sterile normal saline) delivered by an oxygen-driven nebulizer (if available). This treatment should not be delayed, and may be given before the full assessment is completed.

Bronchodilator therapy: The initial dose of rapid-acting bronchodilator may be given by oxygen-driven nebulizer (as described above), or if hypoxemia is absent (or an oxygen-driven nebulizer not available) by either an air-driven nebulizer or a pressurized MDI with spacer and mask or mouthpiece. For most children, the MDI plus spacer is favored as it is more efficient than the nebulizer^{62,108,109} (**Evidence A**) for bronchodilator delivery. The initial dose is two puffs of salbutamol (100 µg per puff) or equivalent. A dose of 2.5 mg salbutamol solution is recommended when a nebulizer is used. The frequency of dosing depends on the response observed over 1 to 4 hours (see below).

Inhaled glucocorticosteroids or leukotriene modifier:

Children who have been prescribed maintenance therapy with inhaled glucocorticosteroids, leukotriene modifier, or both should continue to take the prescribed dose during and after an exacerbation (**Evidence D**).

Assessment of Treatment Response

Children with a severe exacerbation must be observed for at least 1 hour after initiation of treatment, at which time further treatment can be planned.

- If symptoms persist, a further 2 puffs of salbutamol may be given 20 minutes after the first dose and repeated at 20-minute intervals for an hour. Failure to respond to this at 1 hour, or earlier if the child deteriorates, should prompt urgent admission to the hospital and a short course of oral glucocorticosteroids (**Evidence D**).
- If symptoms improve at 1 hour, but recur within 3 or 4 hours, more frequent doses of bronchodilator may be

given (2 or 3 puffs hourly), and oral glucocorticosteroids should be administered. The child should be observed by the family/caregiver and might need to remain in the emergency room or have ready access to emergency care. Children who fail to respond to 10 puffs of inhaled rapid acting β_2 -agonist should be referred to the hospital (**Evidence D**).

- If the symptoms resolve rapidly and do not recur for 1 or 2 hours, no further treatment might be required. The dose of bronchodilator may be repeated every 3 to 4 hours (up to a total of 10 puffs per 24 hours) and, if symptoms persist beyond 1 day, other treatments including inhaled or oral glucocorticosteroids are indicated (**Evidence D**).

Additional Treatment

The addition of a short course of oral glucocorticosteroids or leukotriene modifiers is of doubtful value. Although such interventions have been shown to result in statistically significant benefits in several studies, their clinical benefit, particularly on such endpoints as hospitalizations and longer-term outcomes, have been inconsistent⁹²⁻¹⁰⁰. The exception to this pattern is one study of 1,500 µg of fluticasone propionate daily, which reduced the need for oral glucocorticosteroids from 18% to 8% of subjects¹⁰¹ (**Evidence D**).

Inhaled glucocorticosteroids: For children not previously on inhaled glucocorticosteroids, an initial dose of inhaled glucocorticosteroid twice the low daily dose indicated in **Table 4** may be given and continued for a few weeks or months (**Evidence D**). For those already on inhaled glucocorticosteroids, doubling the dose has not been documented to be effective in older children and there is no evidence to support this approach in children 5 years and younger (**Evidence D**).

Oral glucocorticosteroids: If used, oral glucocorticosteroids (syrup or tablets) are preferred to systemic (intramuscular or intravenous) administration, but are most effective when administered early in an exacerbation. A dose equivalent to prednisolone 1-2 mg/kg/day, with a maximum of 20 mg in children under 2 years of age and 30 mg for children 2-5 years, is recommended (**Evidence D**). A 3-5 day course is sufficient in most children and can be stopped abruptly (**Evidence D**).

Table 8 provides a summary of management of acute severe asthma in children 5 years and younger.

Table 8: Initial Management of Acute Severe Asthma in Children 5 Years and Younger	
Therapy	Dose and Administration
Supplemental oxygen	Deliver by 24% face mask (flow set to manufacturer's instructions, usually 4L/minute) Maintain oxygen saturation above 94%
Short-acting β_2 -agonist	2 puffs salbutamol by spacer, or 2.5 mg salbutamol by nebulizer Every 20 minutes for first hours ^a
Ipratropium	2 puffs every 20 minutes for first hour only
Systemic glucocorticosteroids	Oral prednisolone (1-2 mg/kg daily for up to 5 days) or Intravenous methylprednisolone (1 mg/kg every 6 hours on day 1; every 12 hours on day 2; then daily)
Aminophylline ^b	Consider in ICU: loading dose 6-10mg/kg lean body weight Initial maintenance: 0.9 mg/kg/hour Adjustment according to plasma theophylline levels
Oral β_2 -agonist	No
Long-acting β_2 -agonist	No

^a If inhalation is not possible an intravenous bolus of 5 μ g/kg given over 5 minutes, followed by continuous infusion of 5 μ g/kg/hour.
The dose should be adjusted according to clinical effect and side effects⁸⁴.

^b Loading dose should not be given to patients already receiving theophylline.

Follow-up of Exacerbations

Children who have recently had an asthma exacerbation are at risk of further episodes and require follow-up to ensure complete recovery, to establish the cause of the exacerbation, and, when necessary, to establish appropriate maintenance treatment (**Evidence D**). Prior to discharge from the emergency department or hospital, family/caregivers should receive the following (all are **Evidence D**):

- Instruction on recognition of signs of recurrence and worsening of asthma. The factors that precipitated the exacerbation should be identified and strategies for future avoidance of these factors implemented
- A written individualized action plan including details of accessible emergency services
- A supply of bronchodilator and, where applicable, the remainder of the course of oral or inhaled glucocorticosteroids or leukotriene modifier
- Careful review of inhaler technique
- Further treatment advice:
 - The bronchodilator should be used on an as-needed basis, but the daily requirement should be recorded to assure it is being decreased over time to pre-exacerbation levels
 - Initiate or continued inhaled glucocorticosteroids (for first month after discharge, 3 times low initial dose, then adjust dose as needed)
- A follow-up appointment within 1 week and another within 1-2 months depending on the clinical, social, and practical context of the exacerbation

Before discharge, the condition of the patient should be stable, e.g., out of bed and able to eat and drink without problem.

SUMMARY: KEY MESSAGES

1. The goal of asthma treatment, to achieve and maintain control of the disease, can be achieved in a majority of children 5 years and younger with a pharmacologic intervention strategy developed in partnership between the family/caregiver and the health care practitioner.
2. Maternal smoking during pregnancy and exposure to environmental tobacco smoke early in life are associated with a greater risk of developing wheezing illnesses in childhood, as well as with reduced lung function later in life. Therefore, every effort should be made to avoid exposing children to tobacco smoke.
3. Making a diagnosis of asthma in children 5 years and younger may be difficult because episodic respiratory symptoms such as wheezing and cough are also common in children who do not have asthma, particularly in those younger than 3 years.
4. A diagnosis of asthma in young children can often be made based largely on symptom patterns and on a careful clinical assessment of family history and physical findings. The presence of atopy or allergic sensitization provides additional predictive support, as early allergic sensitization increases the likelihood that a wheezing child will have asthma.
5. Asthma education should be provided to family members and caregivers of wheezy children 5 years and younger when wheeze is suspected to be caused by asthma.
6. For all patients with a confirmed diagnosis of asthma, the goal of treatment is to achieve control of the clinical manifestations of the disease and maintain this control for prolonged periods, with appropriate regard to the safety and cost of the treatment required to achieve this goal.
7. The prolonged use of high doses of inhaled or systemic glucocorticosteroids must be avoided by ensuring that treatment is appropriate and reduced to the lowest level that maintains satisfactory current clinical control.
8. A pressurized metered-dose inhaler (MDI) with a valved spacer (with or without a face mask, depending on the child's age) is the preferred delivery system.
9. Several placebo-controlled studies of inhaled glucocorticosteroids in children 5 years and younger with asthma have found statistically significant clinical effects on a variety of outcomes, including increased lung function and number of symptom-free days, and reduced symptoms, need for additional medication, caregiver burden, systemic glucocorticosteroid use, and exacerbations.
10. Because of the side effects associated with prolonged use, oral glucocorticosteroids in young children with asthma should be restricted to the treatment of acute severe exacerbations, whether viral-induced or otherwise.
11. Rapid-acting inhaled β_2 -agonists are the most effective bronchodilators available and therefore the preferred reliever treatment for asthma in children 5 years and younger.
12. A low-dose inhaled glucocorticosteroid is recommended as the preferred initial treatment to control asthma in children 5 years and younger.
13. If low dose of inhaled glucocorticosteroid does not control symptoms, and the child is using optimal technique and is adherent to therapy, doubling the initial dose of inhaled glucocorticosteroid may be the best option.
14. When doubling the initial dose of inhaled glucocorticosteroids fails to achieve and maintain asthma control, the child's inhalation technique and compliance with the medication regimen should be carefully assessed and monitored, as these are common problems in this age group.
15. Continued need for asthma treatment in children under age 5 should be regularly assessed (e.g., every three to six months).

REFERENCES

1. Global Initiative for Asthma. Global Strategy for Asthma Diagnosis and Prevention. *Global Initiative for Asthma (updated 2008)*. Available from www.ginasthma.org.
2. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schunemann HJ. Going from evidence to recommendations. *BMJ* 2008;336:1049-51.
3. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy* 2004;59:469-78.
4. Bisgaard H, Szeffler S. Prevalence of asthma-like symptoms in young children. *Pediatr Pulmonol* 2007;42:723-8.
5. Kuehni CE, Strippoli MP, Low N, Brooke AM, Silverman M. Wheeze and asthma prevalence and related health-service use in white and south Asian pre-school children in the United Kingdom. *Clin Exp Allergy* 2007;37:1738-46.
6. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. *N Engl J Med* 1995;332:133-8.
7. Sly PD, Boner AL, Bjorksten B, Bush A, Custovic A, Eigenmann PA, *et al*. Early identification of atopy in the prediction of persistent asthma in children. *Lancet* 2008;372:1100-6.
8. Gdalevich M, Mimouni D, Mimouni M. Breast-feeding and the risk of bronchial asthma in childhood: A systematic review with meta-analysis of prospective studies. *J Pediatr* 2001;139:261-6.
9. Gotzsche PC, Johansen HK, Hammarquist C, Burr ML. House dust mite control measures for asthma. *Cochrane Database Syst Rev* 2001:CD001187.
10. Corver K, Kerkhof M, Brussee JE, Brunekreef B, van Strien RT, *et al*. House dust mite allergen reduction and allergy at 4 yr: Follow up of the PIAMA-study. *Pediatr Allergy Immunol* 2006;17:329-36.
11. Marks GB, Mahrshahi S, Kemp AS, Tovey ER, Webb K, Almqvist C, *et al*. Prevention of asthma during the first 5 years of life: A randomized controlled trial. *J Allergy Clin Immunol* 2006;118:53-61.
12. Woodcock A, Lowe LA, Murray CS, Simpson BM, Pipis SD, Kissen P, *et al*. Early life environmental control: Effect on symptoms, sensitization, and lung function at age 3 years. *Am J Respir Crit Care Med* 2004;170:433-9.
13. Bufford JD, Gern JE. Early exposure to pets: Good or bad? *Curr Allergy Asthma Rep* 2007;7:375-82.
14. Ownby DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. *JAMA* 2002;288:963-72.
15. Platts-Mills JA, Custis NJ, Woodfolk JA, Platts-Mills TA. Airborne endotoxin in homes with domestic animals: Implications for cat-specific tolerance. *J Allergy Clin Immunol* 2005;116:384-9.
16. Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, *et al*. Results of a home-based environmental intervention among urban children with asthma. *N Engl J Med* 2004;351:1068-80.
17. Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, *et al*. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. *Eur Respir J* 2008;32:1096-110.
18. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: A population-based cross-sectional study. *Lancet* 2001;357:752-6.
19. O'Hollaren MT, Yunginger JW, Offord KP, Somers MJ, O'Connell EJ, Ballard DJ, Sachs MI. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. *N Engl J Med* 1991;324:359-63.

20. Salo PM, Arbes SJ, Jr., Sever M, Jaramillo R, Cohn RD, London SJ, Zeldin DC. Exposure to *Alternaria alternata* in US homes is associated with asthma symptoms. *J Allergy Clin Immunol* 2006;118:892-8.
21. O'Connor GT, Walter M, Mitchell H, Kattan M, Morgan WJ, Gruchalla RS, *et al.* Airborne fungi in the homes of children with asthma in low-income urban communities: The Inner-City Asthma Study. *J Allergy Clin Immunol* 2004;114:599-606.
22. Greer FR, Sicherer SH, Burks AW. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. *Pediatrics* 2008;121:183-91.
23. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. *Cochrane Database Syst Rev* 2006;3:CD000133.
24. Sears MR, Greene JM, Willan AR, Taylor DR, Flannery EM, Cowan JO, *et al.* Long-term relation between breastfeeding and development of atopy and asthma in children and young adults: A longitudinal study. *Lancet* 2002;360:901-7.
25. Takemura Y, Sakurai Y, Honjo S, Kusakari A, Hara T, Gibo M, Tokimatsu A, *et al.* Relation between breastfeeding and the prevalence of asthma: The Tokorozawa Childhood Asthma and Pollinosis Study. *Am J Epidemiol* 2001;154:115-9.
26. Wright AL, Holberg CJ, Taussig LM, Martinez FD. Factors influencing the relation of infant feeding to asthma and recurrent wheeze in childhood. *Thorax* 2001;56:192-7.
27. Dezateux C, Stocks J, Dundas I, Fletcher ME. Impaired airway function and wheezing in infancy: the influence of maternal smoking and a genetic predisposition to asthma. *Am J Respir Crit Care Med* 1999;159:403-10.
28. Bisgaard H, Loland L, Holst KK, Pipper CB. Prenatal determinants of neonatal lung function in high-risk newborns. *J Allergy Clin Immunol* 2009.
29. Khalequzzaman M, Kamijima M, Sakai K, Chowdhury NA, Hamajima N, Nakajima T. Indoor air pollution and its impact on children under five years old in Bangladesh. *Indoor Air* 2007;17:297-304.
30. Ng'ang'a LW, Odhiambo JA, Mungai MW, Gicheha CM, Nderitu P, Maingi B, *et al.* Prevalence of exercise induced bronchospasm in Kenyan school children: An urban-rural comparison. *Thorax* 1998;53:919-26.
31. Andersen ZJ, Loft S, Ketzel M, Stage M, Scheike T, Hermansen MN, Bisgaard H. Ambient air pollution triggers wheezing symptoms in infants. *Thorax* 2008;63:710-6.
32. Heymann PW, Platts-Mills TA, Johnston SL. Role of viral infections, atopy and antiviral immunity in the etiology of wheezing exacerbations among children and young adults. *Pediatr Infect Dis J* 2005;24:S217-22.
33. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, *et al.* Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. *Am J Respir Crit Care Med* 2008;178:667-72.
34. Lee KK, Hegele RG, Manfreda J, Wooldrage K, Becker AB, Ferguson AC, *et al.* Relationship of early childhood viral exposures to respiratory symptoms, onset of possible asthma and atopy in high risk children: The Canadian Asthma Primary Prevention Study. *Pediatr Pulmonol* 2007;42:290-7.
35. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, *et al.* Environmental exposure to endotoxin and its relation to asthma in school-age children. *N Engl J Med* 2002;347:869-77.
36. von Mutius E, Radon K. Living on a farm: Impact on asthma induction and clinical course. *Immunol Allergy Clin North Am* 2008;28:631-47.
37. Eder W, Klimecki W, Yu L, von Mutius E, Riedler J, Braun-Fahrlander C, *et al.* Association between exposure to farming, allergies and genetic variation in CARD4/NOD1. *Allergy* 2006;61:1117-24.
38. Bjorksten B. Evidence of probiotics in prevention of allergy and asthma. *Curr Drug Targets Inflamm Allergy* 2005;4:599-604.
39. Kozyrskyj AL, Ernst P, Becker AB. Increased risk of childhood asthma from antibiotic use in early life. *Chest* 2007;131:1753-9.

40. Marra F, Lynd L, Coombes M, Richardson K, Legal M, Fitzgerald JM, Marra CA. Does antibiotic exposure during infancy lead to development of asthma?: A systematic review and metaanalysis. *Chest* 2006;129:610-8.
41. Chen E, Langer DA, Raphaelson YE, Matthews KA. Socioeconomic status and health in adolescents: The role of stress interpretations. *Child Dev* 2004;75:1039-52.
42. Wright RJ, Cohen S, Carey V, Weiss ST, Gold DR. Parental stress as a predictor of wheezing in infancy: A prospective birth-cohort study. *Am J Respir Crit Care Med* 2002;165:358-65.
43. Wright RJ, Cohen RT, Cohen S. The impact of stress on the development and expression of atopy. *Curr Opin Allergy Clin Immunol* 2005;5:23-9.
44. Kozyrskyj AL, Mai XM, McGrath P, Hayglass KT, Becker AB, Macneil B. Continued exposure to maternal distress in early life is associated with an increased risk of childhood asthma. *Am J Respir Crit Care Med* 2008;177:142-7.
45. Tollanes MC, Moster D, Daltveit AK, Irgens LM. C esarean section and risk of severe childhood asthma: A population-based cohort study. *J Pediatr* 2008;153:112-6.
46. Roduit C, Scholtens S, de Jongste JC, Wijga AH, Gerritsen J, *et al.* Asthma at 8 years of age in children born by caesarean section. *Thorax* 2009;64:107-13.
47. Rebordosa C, Kogevinas M, Sorensen HT, Olsen J. Pre-natal exposure to paracetamol and risk of wheezing and asthma in children: A birth cohort study. *Int J Epidemiol* 2008;37:583-90.
48. Beasley R, Clayton T, Crane J, von Mutius E, Lai CK, Montefort S, Stewart A. Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: Analysis from Phase Three of the ISAAC programme. *Lancet* 2008;372:1039-48.
49. Doherty G, Bush A. Diagnosing respiratory problems in young children. *Practitioner* 2007;251:20, 22-5.
50. Pedersen S. Preschool asthma-not so easy to diagnose. *Prim Care Respir J* 2007;16:4-6.
51. Elphick HE, Sherlock P, Foxall G, Simpson EJ, Shiell NA, Primhak RA, Everard ML. Survey of respiratory sounds in infants. *Arch Dis Child* 2001;84:35-39.
52. Henderson J, Granell R, Heron J, Sherriff A, Simpson A, Woodcock A, *et al.* Associations of wheezing phenotypes in the first 6 years of life with atopy, lung function and airway responsiveness in mid-childhood. *Thorax* 2008;63:974-80.
53. Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. *Eur Respir J* 2008;31:974-81.
54. Arshad SH, Kurukulaaratchy RJ, Fenn M, Matthews S. Early life risk factors for current wheeze, asthma, and bronchial hyperresponsiveness at 10 years of age. *Chest* 2005;127:502-8.
55. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med* 2000;162:1403-6.
56. Devulapalli CS, Carlsen KC, Haland G, Munthe-Kaas MC, Pettersen M, Mowinkel P, Carlsen KH. Severity of obstructive airways disease by age 2 years predicts asthma at 10 years of age. *Thorax* 2008;63:8-13.
57. Guilbert TW, Morgan WJ, Krawiec M, Lemanske RF, Jr., Sorkness C, Szeffler SJ, *et al.* The Prevention of Early Asthma in Kids study: Design, rationale and methods for the Childhood Asthma Research and Education network. *Control Clin Trials* 2004;25:286-310.
58. Zemek RL, Bhogal SK, Ducharme FM. Systematic review of randomized controlled trials examining written action plans in children: What is the plan? *Arch Pediatr Adolesc Med* 2008;162:157-63.
59. Brouwer AF, Brand PL. Asthma education and monitoring: What has been shown to work. *Paediatr Respir Rev* 2008;9:193-9; quiz 199-200.
60. Swern AS, Tozzi CA, Knorr B, Bisgaard H. Predicting an asthma exacerbation in children 2 to 5 years of age. *Ann Allergy Asthma Immunol* 2008;101:626-30.

61. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, Rosenzweig JC, Manjunath R. Development and cross-sectional validation of the Childhood Asthma Control Test. *J Allergy Clin Immunol* 2007;119:817-25.
62. Castro-Rodriguez JA, Rodrigo GJ. Beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: A systematic review with meta-analysis. *J Pediatr* 2004;145:172-7.
63. Baker JW, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. *Pediatrics* 1999;103:414-21.
64. Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: A dose comparison study. *Am J Respir Crit Care Med* 1999;160:126-31.
65. Chavasse RJ, Bastian-Lee Y, Richter H, Hilliard T, Seddon P. Persistent wheezing in infants with an atopic tendency responds to inhaled fluticasone. *Arch Dis Child* 2001;85:143-8.
66. Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. *Arch Dis Child* 1993;68:85-7.
67. Hoffhuis W, van der Wiel EC, Nieuwhof EM, Hop WC, Affourtit MJ, Smit FJ, et al. Efficacy of fluticasone propionate on lung function and symptoms in wheezy infants. *Am J Respir Crit Care Med* 2005;171:328-33.
68. Ilangovan P, Pedersen S, Godfrey S, Nikander K, Noviski N, Warner JO. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. *Arch Dis Child* 1993;68:356-9.
69. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): Double-blind, randomised, controlled study. *Lancet* 2006;368:754-62.
70. Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. *Am J Respir Crit Care Med* 2000;162:1500-6.
71. Pao CS, McKenzie SA. Randomized controlled trial of fluticasone in preschool children with intermittent wheeze. *Am J Respir Crit Care Med* 2002;166:945-9.
72. Roorda RJ, Mezei G, Bisgaard H, Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. *J Allergy Clin Immunol* 2001;108:540-6.
73. Teper AM, Colom AJ, Kofman CD, Maffey AF, Vidaurreta SM, Bergada I. Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. *Pediatr Pulmonol* 2004;37:111-5.
74. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. *N Engl J Med* 2000;343:1064-9.
75. Pedersen S. Do inhaled corticosteroids inhibit growth in children? *Am J Respir Crit Care Med* 2001;164:521-35.
76. Hakim F, Vilozni D, Adler A, Livnat G, Tal A, Bentur L. The effect of montelukast on bronchial hyperreactivity in preschool children. *Chest* 2007;131:180-6.
77. Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. *Am J Respir Crit Care Med* 2008;178:854-60.
78. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. *Pediatrics* 2001;108:E48.
79. Bisgaard H, Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. *Am J Respir Crit Care Med* 2000;162:187-90.

80. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, Sears MR. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. *Pediatrics* 2007;120:e702-12.
81. Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines as maintenance treatment for asthma in children. *Cochrane Database Syst Rev* 2006:CD002885.
82. Nielsen KG, Bisgaard H. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer. *Am J Respir Crit Care Med* 2001;164:256-9.
83. Tasche MJ, van der Wouden JC, Uijen JH, Ponsioen BP, Bernsen RM, van Suijlekom-Smit LW, de Jongste JC. Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1-4-year-old children with moderate asthma. *Lancet* 1997;350:1060-4.
84. van der Wouden JC, Tasche MJ, Bernsen RM, Uijen JH, de Jongste JC, Ducharme FM. Inhaled sodium cromoglycate for asthma in children. *Cochrane Database Syst Rev* 2003:CD002173.
85. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. *Am J Respir Crit Care Med* 2008.
86. Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. *Pediatrics* 2004;113:e87-94.
87. Leflein JG, Szeffler SJ, Murphy KR, Fitzpatrick S, Cruz-Rivera M, Miller CJ, Smith JA. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: Results of a randomized outcomes trial. *Pediatrics* 2002;109:866-72.
88. Szeffler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. *J Allergy Clin Immunol* 2007;120:1043-50.
89. Kooi EM, Schokker S, Marike Boezen H, de Vries TW, Vaessen-Verberne AA, van der Molen T, Duiverman EJ. Fluticasone or montelukast for preschool children with asthma-like symptoms: Randomized controlled trial. *Pulm Pharmacol Ther* 2008;21:798-804.
90. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. *Cochrane Database Syst Rev* 2006:CD000052.
91. Everard ML, Bara A, Kurian M, Elliott TM, Ducharme F, Mayowe V. Anticholinergic drugs for wheeze in children under the age of two years. *Cochrane Database Syst Rev* 2005:CD001279.
92. Bacharier LB, Phillips BR, Zeiger RS, Szeffler SJ, Martinez FD, Lemanske RF, Jr., et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. *J Allergy Clin Immunol* 2008;122:1127-1135 e8.
93. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. *N Engl J Med* 2006;354:1998-2005.
94. Brunette MG, Lands L, Thibodeau LP. Childhood asthma: Prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection. *Pediatrics* 1988;81:624-9.
95. Fox GF, Marsh MJ, Milner AD. Treatment of recurrent acute wheezing episodes in infancy with oral salbutamol and prednisolone. *Eur J Pediatr* 1996;155:512-6.
96. Grant CC, Duggan AK, DeAngelis C. Independent parental administration of prednisone in acute asthma: A double-blind, placebo-controlled, crossover study. *Pediatrics* 1995;96:224-9.
97. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: Randomised controlled trial. *Lancet* 2003;362:1433-8.
98. Panickar J, Lakhampaul M, Lambert PC, Kenia P, Stephenson T, Smyth A, Grigg J. Oral prednisolone for preschool children with acute virus-induced wheezing. *N Engl J Med* 2009;360:329-38.

99. Robertson CF, Price D, Henry R, Mellis C, Glasgow N, Fitzgerald D, *et al.* Short-course montelukast for intermittent asthma in children: A randomized controlled trial. *Am J Respir Crit Care Med* 2007;175:323-9.
100. Webb MS, Henry RL, Milner AD. Oral corticosteroids for wheezing attacks under 18 months. *Arch Dis Child* 1986;61:15-9.
101. Ducharme FM, Lemire C, Noya FJ, Davis GM, Alos N, Leblond H, *et al.* Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. *N Engl J Med* 2009;360:339-53.
102. National Asthma Council Australia. Written Asthma Action Plans. 2006. Available from www.nationalasthma.org.au/html/management/action_plans/index.asp (assessed 11/14/08).
103. Agrawal SK, Singh M, Mathew JL, Malhi P. Efficacy of an individualized written home-management plan in the control of moderate persistent asthma: A randomized, controlled trial. *Acta Paediatr* 2005;94:1742-6.
104. Burkhart PV, Rayens MK, Revelette WR, Ohlmann A. Improved health outcomes with peak flow monitoring for children with asthma. *J Asthma* 2007;44:137-42.
105. Gibson PG, Ram FS, Powell H. Asthma education. *Respir Med* 2003;97:1036-44.
106. McGrath AM, Gardner DM, McCormack J. Is home peak expiratory flow monitoring effective for controlling asthma symptoms? *J Clin Pharm Ther* 2001;26:311-7.
107. Asthma Management Handbook. National Asthma Council Australia 2006: www.nationalasthma.org.au/cms/index.php (accessed 11/14/08).
108. Deerojanawong J, Manuyakorn W, Prapphal N, Harnruthakorn C, Sritippayawan S, Samransamruajkit R. Randomized controlled trial of salbutamol aerosol therapy via metered dose inhaler-spacer vs. jet nebulizer in young children with wheezing. *Pediatr Pulmonol* 2005;39:466-72.
109. Delgado A, Chou KJ, Silver EJ, Crain EF. Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. *Arch Pediatr Adolesc Med* 2003;157:76-80.

NOTES

COPYRIGHTED MATERIAL -DO NOT ALTER OR REPRODUCE!

The Global Initiative for Asthma is supported by educational grants from:



Mitsubishi Tanabe Pharma



Copies of this document are available at

www.ginasthma.org
www.us-health-network.com

© 2010 Medical Communications Resources, Inc.